Unknown

Dataset Information

0

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

ABSTRACT:

SUBMITTER: Subbiah V 

PROVIDER: S-EPMC4801313 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Subbiah Vivek V   Hong David S DS   Meric-Bernstam Funda F  

Proceedings of the National Academy of Sciences of the United States of America 20160225 11

Similar Datasets

Unknown Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer.
| S-EPMC7410165 | biostudies-literature
Unknown Ceritinib in ALK-rearranged non-small-cell lung cancer.
| S-EPMC4079055 | biostudies-literature
Unknown Crizotinib in ROS1-rearranged non-small-cell lung cancer.
| S-EPMC4264527 | biostudies-literature
Unknown Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
| S-EPMC8590892 | biostudies-literature
Unknown Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
| S-EPMC10380455 | biostudies-literature
Unknown Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
| S-EPMC7066105 | biostudies-literature
Unknown P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
| S-EPMC4739423 | biostudies-literature
Unknown Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.
| S-EPMC4408973 | biostudies-literature
Unknown Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.
| S-EPMC10854608 | biostudies-literature
Unknown Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
| S-EPMC10283448 | biostudies-literature